REGENXBIO Inc.
RGNX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $383 | $785 | $979 | $1,388 |
| - Cash | $58 | $35 | $97 | $345 |
| + Debt | $142 | $89 | $95 | $87 |
| Enterprise Value | $467 | $840 | $977 | $1,129 |
| Revenue | $83 | $90 | $113 | $470 |
| % Growth | -7.7% | -19.9% | -76% | – |
| Gross Profit | $50 | $53 | $58 | $419 |
| % Margin | 59.7% | 58.8% | 51.6% | 89% |
| EBITDA | -$198 | -$239 | -$244 | $170 |
| % Margin | -237.9% | -265.4% | -216.7% | 36% |
| Net Income | -$227 | -$263 | -$280 | $128 |
| % Margin | -272.5% | -292% | -248.7% | 27.2% |
| EPS Diluted | -4.59 | -6.02 | -6.5 | 2.91 |
| % Growth | 23.8% | 7.4% | -323.4% | – |
| Operating Cash Flow | -$173 | -$218 | -$207 | $219 |
| Capital Expenditures | -$2 | -$10 | -$31 | -$84 |
| Free Cash Flow | -$176 | -$228 | -$238 | $135 |